Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P D Lang

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Arzneimittel-Forschung|June 1, 1987
Effect of bezafibrate and colestyramine in patients with primary hypercholesterolemiaE Steinhagen-Thiessen, S Müller, H D Holler, et al.
Pharmatherapeutica|January 1, 1985
Diurnal lipid and lipoprotein profiles with bezafibrate and clofibrate in healthy volunteersP Oster, G Schlierf, P D Lang, et al.
Research in Experimental Medicine. Zeitschrift Fur Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie|January 1, 1982
Fatty acid composition of adipose tissue, blood, lipids, and glucose tolerance in patients with different degrees of angiographically documented coronary arteriosclerosisP D Lang, M Degott, C C Heuck, et al.
European Journal of Clinical Pharmacology|January 1, 1993
A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemiaU Hauf-Zachariou, L Widmann, B Zülsdorf, et al.
Medizinische Klinik|December 8, 1978
[Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia]H R Arntz, U H Klemens, L J Vollmar, et al.
Atherosclerosis|October 1, 1981
Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrateR Mordasini, W Riesen, P Oster, et al.
Atherosclerosis|July 1, 1977
Effect of BM 15.075 on lipoprotein concentrations in different types of hyperlipoproteinaemiaA G Olsson, S Rössner, G Walldius, et al.
Arzneimittel-Forschung|December 1, 1988
Effects of a bezafibrate sustained release formulation on plasma lipoproteins in patients with hypercholesterolemia. Importance of timing of tablet intake for efficacyM Hanefeld, P D Lang, S Fischer, et al.
Atherosclerosis|April 1, 1978
The effect of bezafibrate on the fibrinolytic enzyme system and the drug interaction with racemic phenprocoumonR Zimmermann, W Ehlers, E Walter, et al.
Medizinische Klinik|September 23, 1977
[Treatment of primary hyperlipoproteinemia type IIb and IV. Comparison of the lipid lowering effect of phenformin, clofibrate, and a combination of both (author's transl)]T Koschinsky, P Lenhard, F A Gries, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Arzneimittel-Forschung|June 1, 1987
Effect of bezafibrate and colestyramine in patients with primary hypercholesterolemiaE Steinhagen-Thiessen, S Müller, H D Holler, et al.
Pharmatherapeutica|January 1, 1985
Diurnal lipid and lipoprotein profiles with bezafibrate and clofibrate in healthy volunteersP Oster, G Schlierf, P D Lang, et al.
Research in Experimental Medicine. Zeitschrift Fur Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie|January 1, 1982
Fatty acid composition of adipose tissue, blood, lipids, and glucose tolerance in patients with different degrees of angiographically documented coronary arteriosclerosisP D Lang, M Degott, C C Heuck, et al.
European Journal of Clinical Pharmacology|January 1, 1993
A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemiaU Hauf-Zachariou, L Widmann, B Zülsdorf, et al.
Medizinische Klinik|December 8, 1978
[Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia]H R Arntz, U H Klemens, L J Vollmar, et al.
Atherosclerosis|October 1, 1981
Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrateR Mordasini, W Riesen, P Oster, et al.
Atherosclerosis|July 1, 1977
Effect of BM 15.075 on lipoprotein concentrations in different types of hyperlipoproteinaemiaA G Olsson, S Rössner, G Walldius, et al.
Arzneimittel-Forschung|December 1, 1988
Effects of a bezafibrate sustained release formulation on plasma lipoproteins in patients with hypercholesterolemia. Importance of timing of tablet intake for efficacyM Hanefeld, P D Lang, S Fischer, et al.
Atherosclerosis|April 1, 1978
The effect of bezafibrate on the fibrinolytic enzyme system and the drug interaction with racemic phenprocoumonR Zimmermann, W Ehlers, E Walter, et al.
Medizinische Klinik|September 23, 1977
[Treatment of primary hyperlipoproteinemia type IIb and IV. Comparison of the lipid lowering effect of phenformin, clofibrate, and a combination of both (author's transl)]T Koschinsky, P Lenhard, F A Gries, et al.
Pageof 3